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Introduction
Proper storage, transportation and handling of in-
activated foot and mouth disease (FMD) vaccines
are necessary for successful vaccination campaigns
in areas where the disease is endemic. So, the shelf
life of theses vaccines must be determined (Butcha-
iah et al., 1985).
Guinea pigs are susceptible animals to FMD
and can be protected by aqueous FMD vaccines.
The methods of demonstrating the potency of such
vaccines using guinea pigs have been described
which have a good correlation with the protection
afforded to cattle (Black et al., 1985).
Foot and mouth disease vaccine adjuvanted
with Montanide ISA oil was found to be valid for
more than 2 years when the 50% guinea pig pro-
tective dose (GPPD50) was calculated (Samira et
al., 1999).
FMD quadrivalent oil double emulsion (Mon-
tanide ISA 206) vaccines were tested in sheep. The
oil adjuvant elicited a better immune response at
any time than did the aluminum hydroxide gel vac-
cine (Patil et al., 2002). The immune response of
vaccinated goats with alhydargel and double oil
emulsion Montanide ISA 206 vaccines persisted
for 20 and 36 weeks post challenge, respectively
(Fathia, 2003). Also, Sonia (2007) and Selim et al.
(2010) found that such vaccine induced long last-
ing immunity than that with Alhydragel adjuvant. 
The vaccine shelf life indicated by the manufac-
turer is usually twelve months under the specified
conditions of storage. However, the ultimate shelf
life of these vaccines remains to be determined
(Ferris et al., 1984). The shelf life of an inactivate
oil adjuvant FMD vaccine at 4oC was tested for a
storage period of 15 months, as there was no ap-
preciable vaccine potency loss could be detected
during that period by the direct challenge testing of
vaccinated cattle and antibody assay(Abaracon et
al., 1980;  Doel, 2003 ). In addition, Terpestra et
al. (1994) showed that the potency of two double
oil emulsion (DOE) FMD vaccine after a storage
period of 1 year at 4oC was equal to that obtained
shortly after formulation. Although this potency
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Abstract
The storage stability of locally produced double oil emulsion adjuvant bivalent Foot and mouth disease (FMD) vaccine pre-
pared from type O1/Aga/ EGY/93 strain and A/EGY/1/2006 had been determined depending on its shelf life in different stor-
age temperatures during the registration of this vaccine by the Central Laboratory for Evaluation of Veterinary Biologics,
Abbasia, Cairo. Samples of this vaccine were kept at 4°C for period of 27 months; at 25°C for 5 weeks and at 37°C for 3
weeks. The potency of these vaccine samples was evaluated in guinea pigs as laboratory animal's model. The obtained results
confirmed that the vaccine keep its potency beyond the normal conservation period at 4°C for two years with 100% protection
against challenge with FMDV O1/Aga/EGY/93 and at 25°C for 3 weeks and at 37°C for 1 week, showing 80% protection
when storage of the vaccine at 25°C for 4 weeks; at 37°C for 2 weeks. On challenge with A/EGY/1/2006 the vaccine gave
100% protection when storage at 4°C for 21 months; at 25°C for 2 weeks and at 37°C for 1 week. Otherwise it gave 80%
protection when storage at 4°C for 24 months; at 25°C for 3 weeks and at 37°C for 2 weeks then became invalid after 27
months at 4°C; after 4 weeks at 25°C and for 3 weeks at 37°C. So it could be concluded that 4°C is the best temperature of
choice for storage of the oil inactivated bivalent FMD vaccine.
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had markedly decreased after 2 years yet a standard
dose still induce 50% protection in vaccinated an-
imals. They suggested that DOE vaccine after stor-
age for 2 years provides adequate protection
against field infection.
The mean protective serum antibody titers
against FMD in calves vaccinated with double oil
emulsion (Montanide ISA 206) evaluated by
ELISA and SNT was started at the 3rd week post
vaccination reached the highest antibody level at
the 10th week and continued with the protective
level till the 32nd week post vaccination then began
to decline under the protective level for both FMD
virus types O1/Aga/EGY/93 and A/EGY/1/2006
(Gamil, 2010).
The present work was carried out through the
registration steps of the newly produce bivalent
FMD oil vaccine aiming to provide useful; accurate
and complete information about the vaccine includ-
ing the proper storage periods at different temper-
atures.
Materials and methods
Animals:
Guinea pigs:
Two hundred and fifty Albino apparently healthy
adult guinea pigs of approximately 500 grams body
weight, from lab. Animal house in Veterinary
serum and vaccine research Institute, were used for
preparation of guinea pigs adapted FMD virus, po-
tency test and stability test of FMD bivalent oil
vaccines.
Calves:
Twenty seven apparently healthy native breed
calves of six to eight months old of about 250-300
Kg body weight were used. These calves were
found to be free from antibodies against FMD virus
serotypes O1/Aga/ EGY/93 and A/EGY/1/2006 as
screened by serum neutralization test and ELISA
used for safety and potency (study the efficacy of
the vaccine via challenge and the duration of anti-
body level). 
Viruses:
Locally isolated FMDV type O1/Aga/EGY/93 with
titer 109 TCID50 and type A/EGY/1/2006 with titer
109 TCID50 were supplied by Foot and Mouth Vac-
cine Research Department (FMDRD), Veterinary
Serum and Vaccine Research Institute, Abbasia,
Cairo. The virus type A was confirmed by world
reference laboratory for FMD (WRL) Pirbright
London, UK as A/EGY/1/2006. These viruses were
used for production of the bivalent FMD vaccines,
challenge test.
Cell culture:
Baby Hamster kidney cell line (BHK21) Clone 13
maintained in FMD Department, Abbasia, Cairo
using Eagl's medium with 8-10% sterile bovine
serum, obtained from Sigma Company, USA, was
used for application of serum neutralization test.
Adapation of FMD viruses to guinea pigs:
Foot and mouth disease guinea pig's adapted
viruses were obtained following the method de-
scribed by Carrillo et al. (1990) and Núñez et al.
(2007). 10 male guinea pigs were used for every
virus strain where 3 animals were used for each of
3 successive virus passages keeping one animal as
control. Guinea pigs were inoculated by intra-der-
mal injection in the metatarsal pad of the left hind
foot with 100μl of a viral suspension obtained after
low-speed centrifugation of vesicular fluid and ho-
mogenized tissue in phosphate-buffered saline. An-
imals were euthanized at the 4th day post-infection,
and vesicular fluid and epithelia around the vesicles
were collected, homogenized, and used for further
inoculations.
Preparation of inactivated FMD vaccines:
Foot and mouth disease viruses were propagated in
BHK21 cell line in roller bottles and both virus
types were inactivated with Binary Ethyleneimine
(BEI) according to Bahnemann (1975). The vac-
cine formulation was carried out according to the
method described by Barnett et al. (1996), where
the oil phase consisted of Montanide ISA 206
mixed with the inactivated viruses as equal parts of
an aqueous and oil phase (weight/ weight) and
mixed thoroughly. The vaccine was prepared on the
base that each dose (2 ml) of vaccine contains not
less 108 TCID50/ dose of each virus type.
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Virus titration:
Titration of FMD viruses was carried out using the
micro titer technique (SNT) to detect the infectivity
titer which expressed as log10 TCID50 as de-
scribed by Reed and Muench (1938).
Antigenicity titration:
Antigenicity titration of FMD viruses used in the
preparation of FMD vaccine was carried out by
complement fixation test (CFT) using reference
hyper-immune serum against FMDV. The CFT was
carried out according to the method adopted by
Traub and Manso (1944).
Evaluation of the prepared vaccine:
Montanide ISA206 oil was obtained from Seppic
Company in france. 
Bivalent inactivated montanide ISA206 oil FMD
vaccine was prepared and subjected to the follow-
ing quality control tests:
Sterility test:
It was carried out according to the directions of the
Code of Federal Regulation of USA (1986).Testing
the freedom of the prepared inactivated FMD vac-
cine was done by culturing random samples of such
vaccines on Tryptose phosphate broth; thioglyco-
late media, Sabauraud's dextrose agar and my-
coplasma medium as reported by OIE (2010).
Safety test:
The inactivated FMD viruses were tested for safety
in vitro on BHK21 clone 13 cell line according to
Terpestra et al. (1994) and the safety of the whole
prepared vaccines was tested in vivo in 3 suscepti-
ble calves according to Henderson (1970) by intra-
dermo-lingual inoculation of 1 ml in 10 sites of the
tongue of 3 susceptible calves OIE (2010).
Potency test:
In guinea pigs:
Potency of the prepared vaccine was tested in
guinea pigs according to Black et al. (1985) and
Challa et al. (2011) where 30 guinea pigs were di-
vided into 6 groups. The vaccine potency was de-
termined by calculation of the PD50 of formulated
vaccines by using guinea pigs according to Reed
and Muench (1938).
Experimental design for potency test in calves:
Keeping quality test:
Samples of the prepared DOE bivalent FMD vac-
cine were stored at 4oC; 25oC and 37oC and their
validity was tested on month, week and day inter-
vals through determination of the vaccine potency
in Guinea pigs.
Serological assays:
Serum neutralization test (SNT) described by Fer-
reira (1976) and Enzyme linked immunosrobent
assay (ELISA) according to Voller et al. (1976)
were carried out to determine FMDV induced an-
tibody levels in vaccinated calves.
Results
Results of the present study revealed that FMD
virus used in the vaccine preparation was of high
infectivity and antigenicity titers (Table 1). 
Calculation of GPPD50 was done according to
Reed and Muench (1983), for the bivalent inacti-
vated montanide ISA206 oil adjuvant FMD vac-
cine it was GPPD50 = 88 GPPD50 as shown in
table 2. 
The mean antibody titer against FMDV type
O1/Aga/EGY/93 (animals no. 1-5) started to in-
crease from 0.32 log10 before vaccination to 0.96
log10 after the first week post vaccination and be-
came as a protective titer at the 2nd WPV (1.53
log10), but the mean antibody titer against FMDV
type A/ EGY/1/2006  (animals no. 6-10)  started to
increase from 0.32 log10 before vaccination to 0.78
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Table 1. Infectivity and antigenicity titers of FMD virus
log10 after the first week post vaccination and be-
came as a protective titer at the 3rd WPV (1.89
log10) using SNT but by using ELISA the mean
antibody titer against FMDV type O1/Aga/EGY/93
started to increase from 0.32 log10 before vaccina-
tion to 1.31 log10 after the first week post vacci-
nation and became as a protective titer at the 2nd
WPV (1.8 log10) and the mean antibody titer
against FMDV type A/ EGY/1/2006 started to in-
crease from 0.32 log10 before vaccination to 1.18
log10 after the first week post vaccination and be-
came as a protective titer at the 3rd WPV (2.14
log10). 
The mean antibody titer for control positive
calves before challenge (no. 11-16) remained with
neglected non protected antibody titer till starting
for challenge (0-0.3 log10). Also the mean anti-
body titer for control negative cattle (no. 17-19) re-
mains with neglected non protected antibody titer
till ending of experiment (0-0.3 log10) (Table 3).
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Table 2. GPPD50 for the prepared ISA 206 DOE-FMD vaccines
Table 3. Results of calves vaccinated with inactivated bivalent FMD oil vaccine and challenged with FMD virus strain
O1/Aga/ EGY/93 and A/EGY/1/2006
GPPD50 = 88 GPPD50
*WPV: Weeks post vaccination
The results in table 4, demonstrated that the mean
SNT antibodies titer against FMDV type
A/1/EGY/2006 started to increase from 0.05 log10
before vaccination to reach the peak at the 8th
WPV (2.212 log10), then decreased to become non
protective by the 40th WPV (1.45 log10) but the
mean SNT antibodies titer against FMDV type
O1/Aga/EGY/93 started to increase from (0.122
log10) before vaccination to reach the peak at the
8th WPV (2.241 log10), then decreased to become
non protective by the 40th WPV (1.476 log10).
While the mean ELISA antibodies titer against
FMDV type A/1/EGY/2006 started to increase
from (0.36 log10) before vaccination to reach the
peak at the 8th WPV (2.51 log10), then decreased
to become non protective by the 40th WPV (1.52
log10) and the mean ELISA antibodies titer against
FMDV type O1/Aga/EGY/93 started to increase
from (0.31 log10) before vaccination to reach the
peak at the 4th WPV (2.62 log10), then decreased
to become non protective by the 40th WPV (1.62
log10).
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Table 4. Monitoring the duration of FMD mean antibody titer in vaccinated calves using SNT and ELISA
As shown in table 5, the vaccine keep its po-
tency beyond the normal conservation period at
4°C for at least two years and it induced protection
against challenge with FMDV O1/Aga/ EGY/93 of
100% for storage at 4°C for 24 month then become
invalid but when challenge with FMDV A/1/
EGY/2006 of 100% for storage at 4°C for 21
month then decrease to become 80% at 24 months
but still valid and become invalid at 27 months.
Table 5. Protection % of guinea pigs vaccinated with inactivated bivalent FMD/ ISA206 oil vaccine stored at 4ºC after chal-
lenged with FMD virus type O1/Aga/ EGY/93 or A/EGY/1/2006
As shown in table 6, the vaccine kept its po-
tency beyond the normal conservation period at
25°C for at least 3 weeks and it induced protection
against challenge with FMDV O1/Aga/ EGY/93 of
100% for storage at 25°C for 3 weeks then decrease
to become 80% at 4 weeks but still valid and be-
come invalid at 5 weeks but when challenge with
FMDV A/1/ EGY/2006 of 100% for storage at
25°C for 2 weeks become invalid at 4 weeks. On
the other hand, the vaccine keep its potency beyond
the normal conservation period at 37°C for at least
2 weeks and it induced protection against challenge
with FMDV O1/Aga/ EGY/93 or with FMDV A/1/
EGY/2006 of 100% for storage at 37°C for 1 weeks
then decrease to become 80% at 2 weeks but still
valid and become invalid at 3 weeks (Table 7).
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Table 6. Protection % of guinea pigs vaccinated with inactivated bivalent FMD/ ISA206 oil vaccine stored at 25ºC after chal-
lenged with FMD virus type O1/Aga/ EGY/93 or A/EGY/1/2006
Table 7. Protection % of guinea pigs vaccinated with inactivated bivalent FMD/ ISA206 oil vaccine stored at 37ºC after chal-
lenged with FMD virus type O1/Aga/ EGY/93 or A/EGY/1/2006
Discussion
The obtained results shown in table (1) revealed
that FMD viruses used in the vaccine preparation
had high infectivity and antigenicity titers. It was
found that the prepared bivalent oil FMD vaccine
was free from aerobic and anaerobic bacteria; fungi
and mycoplasma in agreement with the recommen-
dations of the OIE (2010).
Regarding the insurance of complete virus in-
activation, it was found that there was no detection
of cytopathic effect (CPE) on BHK clone 13 indi-
cating that no viable viral residues in all of tested
vaccines. Also no local or general symptoms or le-
sions developed in cattle and there were no changes
in their body temperature. These observations re-
vealed that the tested vaccine is safe as recom-
mended by Henderson (1970) and Terpestra et al.
(1994).
The achieved results showed that the control
non vaccinated animals showed clinical signs of
FMD virus infection after challenge with virulent
virus at different sites of the tongue with body tem-
perature 41oC; salivation, appearance of vesicles
on the mucous membrane of the mouth, tongue
specially at the sites of inoculation and also vesicle
between interdigital space. There were no signs or
lesions of FMD on the vaccinated animals after
challenge. Similar signs were recorded in naturally
and experimentally infected animals by McVicar
and Sutmoller (1972); Arafa (1980); Deeb et al.
(1987) and Musser (2004).
The obtained results were shown in tables (3
and 4) recorded that SNT and ELISA titers were
parallel with each other indicating the validity of
the bivalent oil FMD vaccine on the detected
preservation periods at different temperature for 2
years at 4oC; for 3 weeks at 25oC and for 2 weeks
at 37oC as shown in table (5, 6 and 7). SNT results
against FMDV type O1/Aga/ EGY/93 revealed that
the mean protective antibody titers started at the 2nd
week post vaccination  (1.53 log10), the mean of
antibody titer reached the peak of protective level
at the 8th week post vaccination (2.241 log10) and
the mean of antibody titer continued with protec-
tive level till 36th weeks, then declined under the
protective level, but SNT results against FMDV
type A/EGY/1/2006 results revealed that the mean
protective antibody titers started at the 2nd week
post vaccination  (1.4 log10), the mean of antibody
titer reached the peak of protective level at the 8th
week post vaccination (2.212 log10) and the mean
of antibody titer continued with protective level till
36th weeks, then declined under the protective
level. ELISA results against FMDV type O1/Aga/
EGY/93 revealed that the mean protective antibody
titers started at the 2nd week post vaccination (1.8
log10), the mean of antibody titer reached the peak
of protective level at the 8th week post vaccination
(2.4 log10), but ELISA results against FMDV type
A/EGY/1/2006  revealed that the mean protective
antibody titers started at the 2nd week post vaccina-
tion (1.6 log10), the mean of antibody titer reached
the peak of protective level at the 8th week post vac-
cination (2.51 log10) and the mean of antibody titer
continued with protective level till the 36th weeks,
then declined under the protective level. These lev-
els of FMD neutralizing antibody indices appear to
be higher than the recommended protective titer
(1.5 by SNT and 1.8 by ELISA) as shown by
Moussa et al. (1976); Barteling and Vreeswij
(1991); Halima et al. (1999) and Abd El-Rahman
et al. (2007).
The obtained results were shown in tables (5,6
and 7) confirmed that the vaccine keep its potency
beyond the normal conservation period at 4°C for
at least two years and it induced protection against
challenge with FMDV O1/Aga/ EGY/93 of 100%
for storage at 25°C for 3 weeks and at 37°C for 1
week, showing 80% protection when storage of the
vaccine at 25°C for 4 weeks; at 37°C for 2 weeks.
But after 24 month at 4°C, after 3 weeks at 25°C
and after 2 weeks at 37°C the vaccine became in-
valid. On challenge with A/EGY/1/2006 the vac-
cine gave 100% protection for storage the vaccine
at 4°C for 21 months; at 25°C for 2 week and at
37°C for 1 week, with 80% protection for storage
of the vaccine at 4°C for 24 months; at 25°C for 3
weeks and at 37°C for 2 weeks then became invalid
at 4°C after 27 months; at 25°C after 4 weeks and
at 37°C for 3 weeks. So it could be concluded that
4°C is the best temperature for storage of the oil in-
activated bivalent FMD vaccine where it still valid
for 2 years, but under un recommended tempera-
ture as 25°C it still valid for 4 weeks and at 37°C
still valid for 2 weeks as shown by Black et al.
(1985); Samira et al. (1999); Abaracon et al.
(1980);  Doel (2003) and Terpestra et al. (1994).
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